Navigation Links
Patch Form of HRT Poses Less Clotting Risks Than Pill Does
Date:5/22/2008

Analysis finds pill more than doubles risk while patch only increases it slightly

THURSDAY, May 22 (HealthDay News) -- Women who take hormone replacement therapy via skin patches may face a lower risk of blood clots than women who take the therapy orally.

The new finding could change the risk-benefit ratio for women who are considering hormone therapy to relieve hot flashes, night sweats and other symptoms of menopause.

"One main clinical implication is to consider transdermal rather than oral estrogen for women at high cardiovascular risk in order to avoid thrombosis [blood clots], which is the main harmful effect of short-term hormone therapy," said Dr. Pierre-Yves Scarabin, director of research at the National Institute of Health and Medical Research in France, and senior author of a study published in the May 23 online issue of the British Medical Journal.

Previous studies have found an increased risk not only of blood clots, but also coronary heart disease and breast cancer among postmenopausal women who take hormone replacement therapy (HRT).

But, according to background information in the paper, no one has assessed how high the increased risk is, or whether the risk varies with the type of therapy.

Scarabin and his colleagues reviewed data from eight observational studies and nine randomized controlled trials on HRT and venous thromboembolism (VTE), a potentially fatal blood clot in the vein.

Pool results indicated that the risk of VTE was 2.5 times higher in women taking oral estrogen compared to women taking no estrogen. The risk was most pronounced during the first year of treatment and in women who were overweight or predisposed toward developing blood clots.

By contrast, women currently using the patch had only a slightly elevated risk compared to women taking no estrogen.

Women who had stopped taking HRT saw their risk return to normal.

According to the authors, the increased risk translates into an additional 1.5 events per 1,000 women per year.

Most of the data came from existing observational trials, however, not the gold-standard randomized trials, so the findings should be interpreted with caution, the authors warned.

Other experts agreed.

"It's observational and very interesting, but clearly more studies need to be done," said Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City. "Maybe this opens the door for a way to give hormones more safely to those who need it."

More information

Visit the National Heart, Lung, and Blood Institute for more on hormone replacement therapy.



SOURCES: Pierre-Yves Scarabin, M.D., director, research, National Institute of Health and Medical Research, and cardiovascular epidemiology section, Paul Brousse Hospital, Villejuif, France; Suzanne Steinbaum, D.O., director, women and heart disease, Lenox Hill Hospital, New York City; May 23, 2008, British Medical Journal


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
2. Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine
3. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
4. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
5. PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
6. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
7. Ringing endorsement: Women prefer contraceptive ring over patch
8. FDA Warns Clot Risk Higher in Birth Control Patch Than Pill
9. FDA Renews Warnings on Pain-Relief Patch
10. Studies of 20,000 smokers show quit rates double with counseling and free nicotine patches
11. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patch Form of HRT Poses Less Clotting Risks Than Pill Does 
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... Lean Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. The ... new behaviors and create new habits. The workshops cover a broad range of ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... the Pittsburgh metro area, celebrates the beginning of the latest charity campaign in ... social skills through art. Donations to this worthy cause are currently being accepted ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & Associates ... it’s commitment to act as Agents of Change in the community, announces a ... homeless families to fulfill immediate needs and help them move into permanent housing. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners ... exterior design possibilities. CertainTeed, North America’s leading brand of building products, has improved ... offerings showcased in the mobile version of the ColorView® Exterior Style and Color ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... -- Memorial Hermann Health System has teamed up with Houston ... a one-of-a-kind experience to pediatric patients at Children,s ... 360-degree video and Google Cardboard, Howard was able to ... the patients and their families an unexpected, and energetically ... video . Memorial Hermann IRONMAN Sports ...
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... 12, 2016 --> ... Chronic Inflammation Global Clinical Trials Review, H2, 2015 ... global clinical trials landscape along with top level ... Country (G7 & E7), Trial Status, Trial Phase, ... top companies involved and enlists all trials (Trial ...
Breaking Medicine Technology: